ERASCA INC's ticker is and the CUSIP is 29479A108. A total of 82 filers reported holding ERASCA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $24,430,120 | +173.4% | 10,351,746 | +138.6% | 0.00% | – |
| Q1 2024 | $8,936,503 | +10.6% | 4,338,108 | +14.4% | 0.00% | – |
| Q4 2023 | $8,077,690 | -19.8% | 3,792,343 | -25.9% | 0.00% | – |
| Q3 2023 | $10,076,770 | -44.9% | 5,115,112 | -22.8% | 0.00% | – |
| Q2 2023 | $18,280,117 | +0.5% | 6,623,231 | +9.6% | 0.00% | – |
| Q1 2023 | $18,191,802 | -27.5% | 6,043,788 | +3.7% | 0.00% | -100.0% |
| Q4 2022 | $25,108,137 | -42.5% | 5,825,554 | +4.0% | 0.00% | 0.0% |
| Q3 2022 | $43,689,000 | +56.1% | 5,601,092 | +11.4% | 0.00% | 0.0% |
| Q2 2022 | $27,993,000 | -33.9% | 5,025,759 | +2.0% | 0.00% | 0.0% |
| Q1 2022 | $42,371,000 | +67.1% | 4,926,864 | +202.8% | 0.00% | 0.0% |
| Q4 2021 | $25,354,000 | -41.0% | 1,627,292 | -19.7% | 0.00% | 0.0% |
| Q3 2021 | $43,008,000 | – | 2,026,771 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 11,055,554 | $95,078,000 | 13.59% |
| AH Equity Partners Bio II, L.L.C. | 2,500,000 | $21,500,000 | 12.39% |
| Cormorant Asset Management, LP | 10,505,554 | $90,348,000 | 6.94% |
| EDBI Pte Ltd | 888,888 | $7,644,000 | 5.09% |
| AH Equity Partners LSV II, L.L.C. | 312,500 | $2,688,000 | 1.94% |
| PFM Health Sciences, LP | 4,791,406 | $41,206,000 | 1.54% |
| Artal Group S.A. | 3,172,221 | $27,281,000 | 1.14% |
| AH Equity Partners V, L.L.C. | 50,000 | $430,000 | 1.02% |
| Orbimed Advisors | 1,667,693 | $14,342,000 | 0.23% |
| EcoR1 Capital, LLC | 678,441 | $5,835,000 | 0.18% |